Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Allogeneic NK Cells + Rituximab + Tafasitamab for r/r B-cell NHL
NCT07225439Phase 1Recruiting
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AlloNK in B-cell non-Hodgkin lymphoma. Primary endpoint: Dose Limiting Toxicity up to 42 days. Started Sep 2026; status: recruiting.
02
Drugs
AlloNK
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07225439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225439.